01 / 02
We've funded more than 2500 projects and 1600 researchers to give people affected by a rare genetic condition a new hope.
What we do
We were made to give people affected by a rare genetic condition an answer – treatment for their condition. Rare genetic conditions are not statistically relevant when considered individually, but the same can’t be said about a person’s life.
We support the best projects chosen using a rigorous and transparent selection process, following consultation with an internationally-renowned committee of qualified scientists.
Sofinnova Partners Announces Third Investment from its Italian Fund
This investment brings the total financing by Sofinnova Partners to €25 million over the past six months.
Tigem and SR-Tiget involved in UPGRADE project, funded by the European Union
Fondazione Telethon announces the launch of the UPGRADE project, funded by the European Union with 15 million euros, aiming at developing more precise and effective gene therapies approaches.
Beta Thalassemia: clinical trial provides encouraging evidence for efficacy of gene therapy
Gene therapy, especially if administered early, could be an effective treatment strategy for beta thalassemia, a genetic disease that is quite common in Mediterranean countries, affecting over 7000 patients in Italy only.
How we fund research?
We select the best research projects using an internationally-recognised selection method i.e. the peer review process.
Millions of euros invested